<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149159</url>
  </required_header>
  <id_info>
    <org_study_id>102576</org_study_id>
    <secondary_id>CA209-927</secondary_id>
    <nct_id>NCT03149159</nct_id>
  </id_info>
  <brief_title>Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab</brief_title>
  <official_title>An Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if continued nivolumab with the addition of ipilimumab&#xD;
      plus hypo-fractionated stereotactic radiation (sTR) of a single lesions results in partial or&#xD;
      complete responses in patients with metastatic ccRCC who fail initial treatment with single&#xD;
      agent nivolumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study is withdrawn due to feasibility issues.&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">April 1, 2018</completion_date>
  <primary_completion_date type="Actual">April 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with a partial or complete response</measure>
    <time_frame>12 weeks</time_frame>
    <description>The response rate of combined ipilimumab and nivolumab plus STR will be determined using irRECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>PFS will be determined from the onset of treatment to the time of documented disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab + Ipilimumab + SRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.</description>
    <arm_group_label>Nivolumab + Ipilimumab + SRT</arm_group_label>
    <other_name>opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.</description>
    <arm_group_label>Nivolumab + Ipilimumab + SRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Steriotactic radiation therapy</intervention_name>
    <description>The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.</description>
    <arm_group_label>Nivolumab + Ipilimumab + SRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of metastatic ccRCC.&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Progressive disease after treatment with single-agent nivolumab&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
          -  Presence of measurable disease per RECIST 1.1 criteria&#xD;
&#xD;
          -  Presence of a metastatic lesion greater than 1 cm in size that is amenable to&#xD;
             radiation treatment&#xD;
&#xD;
          -  Adequate organ system function&#xD;
&#xD;
          -  WOCBP and men who are sexually active with WOCBP must agree to use appropriate&#xD;
             method(s) of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are excluded if they have active brain metastases or leptomeningeal&#xD;
             metastases (exceptions outlined in the protocol).&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease, such as systemic lupus erythematosus,&#xD;
             that require treatment with immune suppressing drugs.&#xD;
&#xD;
        Note: Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus,&#xD;
        residual hypothyroidism due to autoimmune condition only requiring hormone replacement,&#xD;
        psoriasis not requiring systemic treatment, or conditions not expected to recur in the&#xD;
        absence of an external trigger&#xD;
&#xD;
          -  Presence of a condition requiring systemic treatment with either corticosteroids (&gt; 10&#xD;
             mg daily prednisone or equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration.&#xD;
&#xD;
        Note: Inhaled or topical steroids and adrenal replacement doses &gt; 10 mg daily prednisone&#xD;
        equivalents are permitted in the absence of active autoimmune disease.&#xD;
&#xD;
          -  Unstable angina or uncontrolled congestive heart failure&#xD;
&#xD;
          -  Uncontrolled hypercalcemia&#xD;
&#xD;
          -  Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus&#xD;
             ribonucleic acid (HCV antibody) indicating acute or chronic infection&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Presence of other malignant diseases, except non-melanoma skin care&#xD;
&#xD;
          -  History of allergy to study drug components.&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to any monoclonal antibody.&#xD;
&#xD;
          -  Anti-cancer treatment including surgery, radiotherapy, chemotherapy, other&#xD;
             immunotherapy, or investigational therapy within 14 days of registration.&#xD;
&#xD;
          -  Women must not be pregnant or breastfeeding. WOCBP must have a negative serum&#xD;
             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days&#xD;
             prior to registration.&#xD;
&#xD;
          -  Any other medical condition for which treatment with ipilimumab or nivolumab would be&#xD;
             medically contraindicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>June 14, 2018</last_update_submitted>
  <last_update_submitted_qc>June 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

